Evaluation of the effect of preprandial ingestion of novel glucomannan containing food on human health.

Evaluation of the effect of preprandial ingestion of novel glucomannan containing food on human health. - Evaluation of the effect of preprandial ingestion of novel glucomannan containing food on human health.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030935

Enrollment

Registered

2018-01-31

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

capsules contains 2g glucomannan powder and TRELAN-G75 at once empty capsules and TRELAN-G75 at once

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: healthy subjects or diabetes patients with HbA1c <8%

Exclusion criteria

Exclusion criteria: diabetes patients with HbA1c >= 8% diabetes patients under treatment patients with severe constipation

Design outcomes

Primary

Measure	Time frame
Suppression of the elevation of plasma glucose	—

Secondary

Measure	Time frame
Elevation of incretin	—

Countries

Japan

Contacts

Public ContactAkihiro Yoshida

Gunma University Hospital Department of Clinical Laboratory Medicine

ayossie10@gunma-u.ac.jp027-220-8576

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026